focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Share News (OVB)

Share Price Information for Ovoca Bio (OVB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.825
Bid: 0.75
Ask: 0.90
Change: 0.00 (0.00%)
Spread: 0.15 (20.00%)
Open: 0.825
High: 0.825
Low: 0.825
Prev. Close: 0.825
OVB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Ovoca Bio plunges on disappointing study results

Thu, 31st Aug 2023 10:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Kodal Minerals PLC, up 21% at 0.52 pence, 12-month change 0.20-0.93p. The West Africa-focused mineral explorer and developer says its subsidiary Kodal Mining UK Ltd, Hainan Mining Co Ltd and Hainan's subsidiary Xinmao Investment Co Ltd have approved an extension for the Bougouni lithium project funding package, originally announced in January. Deadline moves to September 30 from August 31. Continues to work with the Mali government to finalise the remaining compliance that will complete the funding. Notes all approvals have been obtained from the Chinese government. Adds that it has also completed the full registration of a new mining company, Le Mines de Lithium de Bougouni SA, which is a 100% subsidiary of Kodal Mining UK.

----------

Crossword Cybersecurity PLC, up 7.7% at 7.00 pence, 12-month range 6.00-26.00p. The cybersecurity firm expects to report revenue of GBP1.9 million in the six months ended June, up 27% from the year prior. Notes there has not been a slowdown in cybersecurity spending among its core regulated and critical national infrastructure clients. Consequently, expects to meet market expectations for full-year revenue. Adds its overall gross margin improved by 4 percentage points in the first half of the year and its administrative expenses have stabilised. Eyes a revenue growth rate of 30% for 2024 and aims to deliver earnings before interest, tax, depreciation and amortisation and cash breakeven on a monthly basis during the second half of 2024.

----------

AIM - LOSERS

----------

Ovoca Bio PLC, down 82% at 2.50 pence, 12-month range 2.50-14.80p. The women's health-focused biopharmaceutical company announces that the top-line results from its phase two dose-ranging study assessing Orenetide did not show statistically significant superiority versus placebo on its co-primary endpoints. The study evaluated the effect of a range of daily administered Orenetide doses on a lack or loss of sexual desire in 667 women. Its co-primary endpoints were sexual desire, as measured by the female sexual function index desire domain, and the degree to which a participant is bothered by low sexual desire, as measured by the female sexual distress scale. Other secondary efficacy endpoints were also shown not to have statistically significant differences versus a placebo.

----------

Eneraqua Technologies PLC, down 22% at 73.99 pence, 12-month range 60.00-389.60p. The energy and water efficiency solutions provider expects revenue to be at least GBP26.0 million in the first half of its financial year, up from GBP24.3 million the year prior. Also expects to be profitable on an earnings before interest, tax, depreciation and amortisation basis, in line with expectations. However, notes that the UK government intends to change the legislation that governs development in nitrate-sensitive areas. Says announcement was unexpected and company is waiting to fully understand the implications of the proposals. Expects clients to delay projects until there is greater clarity. Expects this will "materially impact" its ability to deliver against its original budget. Consequently, expects Ebitda in the full-year will be "materially below" current market expectations of GBP8.8 million.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 Oct 2020 10:54

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Read more
2 Oct 2020 10:10

Ovoca Bio hits stumbling block in Russia drug approval

(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that was submitted to the Russian Ministry of Health (Minzdrav) in September 2019.

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
21 Sep 2020 21:19

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

Read more
26 Jun 2020 11:58

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Read more
24 Mar 2020 18:39

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Read more
16 Sep 2019 11:33

Ovoca Bio narrows losses as BP-101 trials continue

(Sharecast News) - Biopharmaceutical firm Ovoca Bio narrowed losses slightly in the first half of its trading year, while focus remained firmly on its continued development of a treatment for female sexual dysfunction.

Read more
16 Sep 2019 10:48

Ovoca Bio Interim Loss Widens On Administration Expenses

(Alliance News) - Ovoca Bio PLC on Monday said its loss widened in the first half of the year, suffering higher administration expenses in the year as it worked to develop its BP-101 female sexual

Read more
28 Aug 2019 14:43

Ovoca Bio Non-Executive Nikolay Myasoyedov Leaves For Personal Reasons

(Alliance News) - Ovoca Bio PLC on Wednesday said Non-Executive Director Nikolay Myasoyedov intends to step down from the board with immediate effect for personal reasons.The pharmaceutical

Read more
8 Aug 2019 11:24

Ovoca Bio's Libicore Application Result Expected A Year After Filing

(Alliance News) - Ovoca Bio PLC on Thursday said it intends to file for the approval of its Libicore female sexual dysfunction drug later in the quarter and expects the verdict in a year's 16%

Read more
26 Jul 2019 17:03

Ovoca Bio Says Non-Executive Director Yuri Radchenko Has Left Role

(Alliance News) - Drug company Ovoca Bio PLC said on Friday Yuri Radchenko, a non-executive director, has stepped down with immediate effect due to personal reasons.Chief Executive Kirill I

Read more
28 Jun 2019 15:07

Ovoca Bio Loss Widens; Prepares For Market Approval Filing For Libicore

(Alliance News) - Ovoca Bio PLC on Friday said its annual loss widened heavily as a result of administration expenses and said it is preparing to file for marketing approval of its drug BP101 in a

Read more
23 Apr 2019 15:40

Ovoca Bio's IVIX ropes in Biorasi for development of 'Libicore' drug candidate

(Sharecast News) - Ovoca Bio announced on Tuesday that its subsidiary IVIX has begun the process of preparing an integrated clinical development plan for its investigational drug candidate, 'Libicore' (BP-101), for both the US and EU regions with US-based contract research organisation Biorasi.

Read more
27 Mar 2019 10:21

Ovoca Bio Expands IVIX Stake Amid Strong Libicore Drug Trial Results

LONDON (Alliance News) - Ovoca Bio PLC said Wednesday it increased its stake in a majority-owned subsidiary following a positive set of test results from its Libicore sexual desire - known as Gold

Read more
25 Mar 2019 12:13

Ovoca Bio To Seek Russian Approval For Libicore After Successful Trial

LONDON (Alliance News) - Ovoca Bio PLC on Monday said it intends to file for the approval of its hypoactive sexual desire disorder drug Libicore in Russia after positive results from a recent in a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.